Feraheme (Ferumoxytol) Should Be Avoided Before 13 Weeks Gestation
Avoid intravenous iron, including Feraheme, prior to 13 weeks gestation 1. This is the clear expert consensus recommendation from the most recent 2024 guidelines on intravenous iron administration.
Key Safety Considerations
FDA Labeling and Animal Data
The FDA label for Feraheme indicates limited available data with ferumoxytol use in pregnant women are insufficient to inform drug-associated risk 2. Critical animal studies revealed:
- In rabbits, ferumoxytol at maternally toxic doses (6 times human dose) caused fetal malformations and decreased fetal weights during organogenesis 2
- These effects occurred specifically during the period equivalent to first trimester development
- At lower doses (2 times human dose), no maternal or fetal effects were observed
Maternal Hypersensitivity Risk
Severe adverse reactions including circulatory failure, severe hypotension, and shock may occur in pregnant women with parenteral iron products, which can cause fetal bradycardia, especially during second and third trimester 2. While this warning emphasizes later trimesters, the risk exists throughout pregnancy.
Clinical Algorithm for First Trimester
If iron deficiency anemia is identified in first trimester:
- Delay IV iron until after 13 weeks gestation 1
- Use oral iron supplementation if tolerated during weeks 1-13
- If severe anemia threatens maternal health, weigh risks of untreated IDA (preterm delivery, low birth weight) against potential fetal risks 2
- After 13 weeks, ferumoxytol can be administered as 510 mg twice (one week apart) or 1020 mg once 3
Evidence After First Trimester
Once past 13 weeks, ferumoxytol demonstrates excellent safety and efficacy. A study of 131 consecutive second- and third-trimester pregnant women receiving ferumoxytol reported no adverse events with highly significant hemoglobin improvements 3. However, this evidence specifically excluded first trimester patients.
Critical Pitfall
The main pitfall is assuming all IV iron formulations have equivalent pregnancy data. Ferumoxytol specifically caused fetal malformations during organogenesis in animal studies 2, making first trimester avoidance particularly important compared to simply lacking data.